Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia

Blood

Volumn 88, Issue 7, 1996, Pages 2473-2479

  Beran, Miloslav ^a   Kantarjian, Hagop ^b   O'Brien, Susan ^b   Koller, Charles ^b   Al Bitar, Maher ^b   Arbuck, Susan ^b   Pierce, Sherry ^b   Moore, Michael ^b   Abbruzzese, James L ^b   Andreeff, Michael ^b   Keating, Michael ^b   Estey, Elihu ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; TOPOTECAN;

ADULT; AGED; ARTICLE; BLAST TRANSFORMATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GENE MUTATION; HUMAN; KARYOTYPE; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; ONCOGENE; PRIORITY JOURNAL; REMISSION; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 10144234806     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.7.2473.bloodjournal8872473     Document Type: Article

References (42)

1. Beran M: Treatment of myelodysplastic syndromes, in Freireich E, Kantarjian H (eds): Therapy of Hematopoietic Neoplasia. New York, NY, Dekker, 1991, p 35
2. Bennett JM: Classification of the myelodysplastic syndromes. Clin Haematol 15:909, 1986
3. Aul C, Gattermann N, Germing U, Runde V, Heyll A, Schneider W: Risk assessment in primary myelodysplastic syndromes: Validation of the Düsseldorf score. Leukemia 8:1906, 1994
4. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bauters F, Fenaux P: Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 1315, 1993
5. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton D, Gralnick H, Sultan C, Cox C: The chronic myeloid leukaemias: Guidelines for distinguishing chronic granulocytic, atypical chronic myeloid and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87:746, 1994
6. Michaux JL, Martiat P: Chronic myelomonocytic leukaemia (CMML) - A myelodysplastic or myeloproliferative syndrome? Leuk Lymphoma 9:35, 1993
7. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Smith TL, Talpaz M, Beran M, Cork A, Trujillo JM, Freireich FJ: Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 58:2023, 1986
8. Elias L, Hoffman R, Boswell S, et al: A trial of recombinant alpha-interferon in the myelodysplastic syndromes: 1 Clinical results. Leukemia 1:105, 1987
9. Koeffler HP, Heitjan D, Mertelsmann R, et al: Randomized study of 13-cis-retin acid versus placebo in the myelodysplastic disorders. Blood 71:703, 1987
10. Clark RE, Ismail SAD, Jacobs A, et al: A randomized trial of 13-cis-retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome. Br J Haematol 66:77, 1987
11. Arcenas AG, Vadhan-Raj S: Hematopoietic growth factor therapy of myelodysplastic syndromes. Leuk Lymphoma 11:65, 1993
12. Gerhartz HH, Marcus R, Delmer A, Zwierzina H, Suciu S, Dardenne M, et al: A randomized phase II study of low-dose cytosine arabinoside (LD-Ara-C) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. Leukemia 8:16, 1994
13. Cheson BD, Jasperse DM, Simon R, Friedman MA: A critical appraisal of low-dose cytosine arabinoside in patients with acute nonlymphocytic leukemia and myelodsyplastic syndromes. J Clin Oncol 4:1857, 1986
14. Greenberg B, Reynolds R, Charron CB, Squillace KM, Lessin LS, Case DC, Gams RA: Treatment of myelodysplastic syndromes with daily oral Idarubicin. Cancer 71:1989, 1993
15. Fenaux P, Morel P, Rose C, et al: Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77:497, 1988
16. Estey E, Pierce S, Kantarjian H, O'Brien S, Beran M, Andreeff M, Escudier S, Koller C, Kornblau S, Robertson L, Keating M: Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma 11:59, 1993
17. DeWitte T, Zwaan F, Hermans H, et al: An EGBMT survey on allogeneic bone marrow transplantation for secondary leukemia and bad prognosis myelodysplastic syndromes. Bone Marrow Transplant 4:9, 1989
18. Anderson JE, Appelbaum F, Schoch G, Gooley T, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Chauncey T, Clift RA, Deeg HJ, Doney K, Flowers M, Hansen JA, Martin PJ, Matthews DC, Nash RA, Sanders JE, Shulman H, Sullivan KM, Witherspoon RP, Storb R: Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: A phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14:220, 1996
19. Liu LF: DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 58:351, 1989
20. Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase target chemotherapy of human colon cancer xenografts. Science 246:1046, 1989
21. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16, 1992
22. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11: A new camptothecin derivative, in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 10:189, 1991 (abstr)
23. Ohno R, Okada K, Masoka T, et al: An early phase II study of CPT-11: A new derivative of camptothecin for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907, 1990
24. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating JM, Estey EH: Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81:1146, 1993
25. Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng Y-C, Gorchow LB, Kaufman SH: Phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12:2193, 1994
26. Estey E, Keating MJ, Dixon D, Trujillo JM, McCredie KB, Freireich E: Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic myelogenous leukemia. Hematol Pathol 1:203, 1987
27. Trujillo JM, Cork A, Ahearn MJ: Hematologic and cytologic characteristics of 8;21 translocation acute granulocytic leukemia. Blood 53:659, 1979
28. LeMaistre A, Lee MS, Talpaz M, Kantarjian HM, Freireich EJ, Deisseroth AB, Trujillo JM, Stass SA: RAS oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood 73:889, 1989
29. Nakagawa T, Saitoh S, Inito S, et al: Multiple point mutations of N-ras and K-ras oncogene in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 49:114, 1992
30. Silverman L, Holland J, Weinberg R, Alter B, Davis B, Ellison R, Demakos E, Cornell C, Carey R, Schiffer C, Frei E, McIntyre OR: Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7:21, 1993
31. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Institute, 1988
32. Gehan E: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346, 1961
33. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:157, 1958
34. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
35. Erlich H, Bugawan T, Begovich AB, Scharf S, Griffith R, Saiki R, Higuchi R, Walsh PS: HLA-DR, DQ and DP typing using PCR amplification and immobilized probes. Eur J Immunogen 18:33, 1991
36. Cai SP, Wall J, Kan YW, Chehab FF: Reverse dot blot probes for the screening of beta-thalassemia mutations in Asians and American blacks. Hum Mutat 3:59, 1994
37. Cuppens H, Marynen P, De Boeck C, Cassiman JJ: Detection of 98.5% of the mutations in 200 Belgian cystic fibrosis alleles by reverse dot-blot and sequencing of the complete coding region and exon/intron junctions of the CFTR gene. Genomics 18:693, 1993
38. Pinto A, and Zagonel V: 5-Aza-2′-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends. Leukemia 7:51, 1993
39. Anzai H, Frost P, Abbrussese JL: Synergistic cytoxicity with 2′-deoxy-5-azacytidine and topotecan in vitro and in vivo. Cancer Res 52:2180, 1992
40. Cogswell PC, Morgan R, Dunn M, Neubauer A, Nelson P, Polland-Johnston NK, Sandberg AA, Liu E: Mutations of the RAS protooncogenes in chronic myelogenous leukemia: A high frequency of RAS mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood 74:2629, 1989
41. Ginsberg CH, LeMaistre AC, Kantarjian H, Talpaz M, Cork A, Freireich E, Trujillo JM, Lee M-S, Stass SA: RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 76:1214, 1990
42. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H: Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268, 1995